-
Bilex Pharma Completes Patient Enrollment for Landmark Phase 3 Trial of RSV Vaccine Candidate BLX-RSV01 in Older Adults
Bilex Pharma today announced the successful completion of patient enrollment in the pivotal Phase 3 clinical trial (RSV-301) evaluating the efficacy, safety, and immunogenicity of BLX-RSV01, its investigational vaccine candidate designed to protect older adults (aged 60 years and above) against Respiratory Syncytial Virus (RSV). Achieving a Critical Milestone in Late-Stage Development Reaching full enrollment…
-
Bilex Pharma’s Next-Generation COVID-19 Vaccine BLX-COVID19 Shows Superior Immune Response with Reduced Dosing in Phase 2 Trial
Bilex Pharma today announced highly encouraging results from its Phase 2 clinical trial evaluating BLX-COVID19, the company’s next-generation COVID-19 vaccine candidate based on its proprietary self-amplifying mRNA (saRNA) platform. The study demonstrated that BLX-COVID19 elicited significantly higher levels of immune responses compared to baseline expectations for first-generation mRNA vaccines, even at considerably lower dose levels.…
-
Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
Bilex Pharma is honoured to announce it has been awarded a significant grant of £15 million from the Coalition for Epidemic Preparedness Innovations (CEPI). This crucial funding will accelerate the development and validation of Bilex Pharma’s rapid-response vaccine platform, a key component of its Project RESPOND pandemic preparedness initiative. Strengthening Global Defences Against Future Pandemics CEPI is…
-
Bilex Pharma’s Universal Influenza Vaccine Candidate Shows Promising Cross-Strain Protection in Phase 2b Interim Analysis
Bilex Pharma today announced promising interim results from its ongoing Phase 2b clinical trial evaluating BLX-FLU03, the company’s investigational universal influenza vaccine candidate. The analysis suggests that BLX-FLU03 induces cross-reactive immune responses against diverse influenza strains, a key step towards developing a vaccine offering broader and potentially more durable protection than current seasonal options. Moving…
-
Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial
Bilex Pharma today announced positive topline results from the Phase 1 clinical trial of BLX-DEN01, its tetravalent dengue vaccine candidate. The study demonstrated that BLX-DEN01 was well-tolerated and, crucially, induced balanced neutralizing antibody responses against all four dengue virus (DENV) serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Addressing a Major Challenge in Dengue Vaccine Development Dengue…
-
Bilex Pharma Announces Breakthrough in Thermostable Vaccine Technology, Enhancing Global Access Potential
Bilex Pharma today announced a significant advancement in its vaccine technology platform, achieving enhanced thermostability for its mRNA vaccine formulations. This breakthrough has the potential to dramatically reduce the reliance on complex ultra-cold chain logistics, a major step towards improving global vaccine access and equity, particularly in resource-limited settings. Overcoming the Cold Chain Challenge Many…
-
Bilex Pharma’s Manchester Manufacturing Facility Receives MHRA Approval for Commercial Vaccine Production
Bilex Pharma is delighted to announce a significant operational milestone: our state-of-the-art vaccine manufacturing facility in Manchester has received full regulatory approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for commercial Good Manufacturing Practice (GMP) production. A Landmark Achievement in Operational Readiness This approval confirms that our Manchester facility, operations, and rigorous…
-
Bilex Pharma Forms Strategic Partnership with PATH to Accelerate Development of Innovative Malaria Vaccine Candidate
Bilex Pharma is thrilled to announce a new strategic partnership with PATH, a global non-profit dedicated to health equity, to accelerate the development of our promising malaria vaccine candidate, BLX-MAL01. This collaboration brings together Bilex Pharma’s cutting-edge vaccine technology platforms with PATH’s extensive expertise in malaria and its decades of experience advancing vaccines for low-resource…
-
BLX-CHIK01 Chikungunya Vaccine Enters Clinical Trials Following Successful Preclinical Studies
Bilex Pharma is pleased to announce the initiation of Phase 1 clinical trials for BLX-CHIK01, our virus-like particle (VLP) vaccine candidate for chikungunya virus. This important milestone follows the successful completion of comprehensive preclinical studies demonstrating the vaccine’s strong immunogenicity and favorable safety profile. Addressing a Growing Global Health Threat Chikungunya virus is a mosquito-transmitted…
-
Bilex Pharma’s Nipah Virus Vaccine Shows 100% Protection in Preclinical Challenge Studies
Bilex Pharma is pleased to announce that BLX-NIPAH01, our investigational mRNA vaccine candidate against Nipah virus, has demonstrated complete protection in preclinical challenge studies. This significant milestone advances our efforts to develop a vaccine against this deadly emerging pathogen with pandemic potential. Addressing a Serious Emerging Threat Nipah virus is a zoonotic pathogen that causes…
About
At Bilex Pharma, we envision a world where innovative vaccines provide effective protection against both established and emerging infectious diseases, enabling healthier communities and more resilient global health systems.
We focus our expertise on significant health challenges where current solutions are inadequate or nonexistent. By targeting diseases with substantial global burden and limited preventive options, we strive to make meaningful contributions to public health where they’re needed most.
Archive
Categories
Recent Posts
- Bilex Pharma Completes Patient Enrollment for Landmark Phase 3 Trial of RSV Vaccine Candidate BLX-RSV01 in Older Adults
- Bilex Pharma’s Next-Generation COVID-19 Vaccine BLX-COVID19 Shows Superior Immune Response with Reduced Dosing in Phase 2 Trial
- Bilex Pharma Awarded £15 Million Grant from CEPI to Accelerate Development of Pandemic Preparedness Platform
- Bilex Pharma’s Universal Influenza Vaccine Candidate Shows Promising Cross-Strain Protection in Phase 2b Interim Analysis
- Bilex Pharma’s Dengue Vaccine Candidate BLX-DEN01 Demonstrates Balanced Immune Response Against All Four Serotypes in Phase 1 Trial